XNASCYTHW
Market cap22mUSD
Jan 13, Last price
0.29USD
1D
16.00%
1Q
20.83%
Name
Cyclo Therapeutics Inc
Chart & Performance
P/E
—
P/S
7.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
82.01%
Rev. gr., 5y
1.25%
Revenues
1m
-21.76%
Net income
-20m
L+31.27%
CFO
-16m
L+7.08%
Earnings
Mar 17, 2025
Profile
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 1,076 -21.76% | 1,376 -13.24% | |||||||
Cost of revenue | 19,946 | 16,957 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (18,870) | (15,581) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (171) | ||||||||
Tax Rate | |||||||||
NOPAT | (18,870) | (15,410) | |||||||
Net income | (20,057) 31.27% | (15,280) 6.81% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 9,739 | 160 | |||||||
BB yield | -37.51% | -1.33% | |||||||
| Debt | |||||||||
Debt current | 2,021 | ||||||||
Long-term debt | 1,078 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | (22) | 3,481 | |||||||
Net debt | (6,147) | (1,543) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (16,185) | (15,114) | |||||||
CAPEX | (2) | (15) | |||||||
Cash from investing activities | (2) | 38 | |||||||
Cash from financing activities | 23,891 | 7 | |||||||
FCF | (19,742) | (15,390) | |||||||
| Balance | |||||||||
Cash | 9,247 | 1,543 | |||||||
Long term investments | |||||||||
Excess cash | 9,193 | 1,475 | |||||||
Stockholders' equity | (83,854) | (63,799) | |||||||
Invested Capital | 90,655 | 64,533 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 16,330 | 8,439 | |||||||
Price | 1.59 11.97% | 1.42 -61.93% | |||||||
Market cap | 25,964 116.66% | 11,984 -49.56% | |||||||
EV | 19,817 | 10,440 | |||||||
EBITDA | (18,850) | (15,562) | |||||||
EV/EBITDA | |||||||||
Interest | 150 | ||||||||
Interest/NOPBT | |||||||||